Check Out What’s New at Goldfinch

03.22.22

Goldfinch Bio to Host Virtual Event on Unmet Need in Focal Segmental Glomerulosclerosis (FSGS) and GFB-887 as a Novel Kidney Precision Medicine Candidate

02.28.22

Goldfinch Bio Announces Positive Preliminary Data from Phase 2 Clinical Trial Evaluating GFB-887 as a Precision Medicine for Patients with Focal Segmental Glomerular Sclerosis (FSGS)

02.23.22

Goldfinch Bio to Participate in Upcoming Industry Conferences

01.24.22

Goldfinch Bio Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

12.06.21

Goldfinch Bio Strengthens Leadership Team with Appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer